NEW YORK, November 6, 2005 A team of researchers led by scientists at Memorial Sloan-Kettering Cancer Center have discovered that a new class of drugs -- now in early stage clinical trials -- work best in patients with mutations in the BRAF gene. BRAF is a protein that plays a central role in the growth and survival of cancer cells and is mutated in the majority of patients with melanoma and in a minority of patients with colon, breast, and lung cancers. The findings, available in an advance online publication of Nature, represent a potential targeted therapy tailored for patients whose tumors contain this mutation.
The researchers found that drugs that inhibit a protein called MEK selectively inhibited the growth of cancer cells lines and tumors that have a mutated BRAF gene. One of these drugs, PD0325901 (developed by Pfizer Research and Development), is now being tested in clinical trials of patients with melanoma, colon, breast, and lung cancers. In addition, by re-analyzing the data on more than 42,000 compounds tested by the National Cancer Institute against a panel of 60 cancer cell lines, the investigators were able to identify a small number of other compounds that also selectively inhibit tumors that have the BRAF mutation. While the mechanism of action of some of these compounds has yet to be determined, several of the most effective compounds were also inhibitors of the MEK protein.
"We find that all tumors with the BRAF mutation and some with the RAS mutation are sensitive to drugs that inhibit MEK," explained Dr. Neal Rosen, Professor of Medicine and a member and laboratory head in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering and the study's senior author. "Translating these findings into a strategy for treating patients whose tumors are dependent upon this specific genetic change is the next step, and such clinical trials are now ongoing."
"The BRAF mutation was first identified by a conPage: 1 2 Related biology news :1
Contact: Joanne Nicholas
Memorial Sloan-Kettering Cancer Center
. Mutations point the way to new leukemia drugs2
. Mutations in NOTCH1 gene cause aortic valve disease3
. Mutations in transporter protein shed light on neurodegenerative disorders4
. Mutations in transporter protein effect HDL levels in the general population5
. Link between sunspots, rain helps predict disease in east Africa6
. Gene predicts better outcome as cortex normalizes in teens with ADHD7
. Success or failure of antidepressant citalopram predicted by gene variation8
. MIT model could predict cells response to drugs9
. New research identifies anti-viral protein that may predict who might be at risk to develop lupus10
. Study points to new way to predict death risk from torn aorta11
. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer